Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

Bo Hu(Central South University), Shengyuan Yu(Nankai University), Xiang Li(Shandong University), Gang Li(Tongji University), Xiaohong Li(Shandong University), Junpeng Zhuang(Lilly (China)), Hongru Zhao(Soochow University), Zhihua Jia(Chinese PLA General Hospital), Shan Wu(Jilin University), Tingmin Yu(Second Affiliated Hospital of Jilin University)
The Journal of Headache and Pain
July 28, 2022
Cited by 37


Related Papers